Parathyroid hormone helping bone cells use marrow fat
Parathyroid hormone (PTH) modulates lipid metabolism in the skeletal niche
['FUNDING_R01'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-11466947
This project looks at whether intermittent parathyroid hormone helps bone cells use fat in the marrow to build stronger bones for people with osteoporosis or low bone density.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-11466947 on ClinicalTrials.gov |
What this research studies
As someone with low bone density, I'd hear that researchers are exploring how intermittent parathyroid hormone (the kind already used to boost bone formation) changes fat inside the bone marrow and how bone cells use that fat. They are testing two linked ideas: that the hormone makes marrow fat cells release lipid molecules, and that bone-building osteoblasts increase their use of those lipids for energy. The team uses lab-based molecular experiments, cell models, and likely animal models to trace lipid release and uptake within the skeletal niche. The aim is to map these steps so future therapies can better support the energy needs of bone formation.
Who could benefit from this research
Good fit: People with osteoporosis or osteopenia who are interested in new anabolic approaches to increase bone formation would be the most likely to benefit from advances stemming from this work.
Not a fit: People without bone loss or those with bone diseases unrelated to PTH signaling or marrow lipid metabolism may not see direct benefit from this line of research.
Why it matters
Potential benefit: If successful, this work could point to ways to boost bone formation with fewer side effects by targeting how bone cells use lipids in the marrow.
How similar studies have performed: Intermittent PTH (for example, teriparatide) is already known to increase bone formation clinically, but connecting PTH's benefits to marrow lipid metabolism is a newer and less-tested concept.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RENDINA-RUEDY, ELIZABETH — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: RENDINA-RUEDY, ELIZABETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.